26478-16-0

Basic information

• Product Name: 2,2-(Bromoethyl)thiophene
• Synonyms: Bromoethylthiophene;2-(2-Bromoethyl)thiophene;2-(2-Thienyl)ethyl BroMide
• CAS NO: 26478-16-0
• Molecular Formula: C₆H₇BrS
• Molecular Weight: 191.08878
• EINECS: 1533716-785-6
• Mol File: 26478-16-0.mol

Chemical Properties

• Boiling Point: 205.751 °C at 760 mmHg
• Flash Point: 78.236 °C
• Appearance: white crystal
• Density: 1.53 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• Solubility: Chloroform (Slightly), Hexane (Slightly), Methanol (Slightly)
• Stability: Light and temperature sensitive
• CAS DataBase Reference: 2,2-(Bromoethyl)thiophene(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-(Bromoethyl)thiophene(26478-16-0)
• EPA Substance Registry System: 2,2-(Bromoethyl)thiophene(26478-16-0)

Safety Data

• Hazardous Substances Data: 26478-16-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,2-(Bromoethyl)thiophene is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows it to be a key component in the synthesis of potent analgesics, such as C8813, which is known for its effective pain-relieving properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2,2-(Bromoethyl)thiophene serves as a valuable building block for creating a wide range of thiophene-based compounds. Its reactivity and functional groups make it suitable for further modification and incorporation into more complex molecules, which can be applied in various industries, including materials science, electronics, and pharmaceuticals.
Used in Research and Development:
2,2-(Bromoethyl)thiophene is also utilized in research and development settings, where it can be employed to study the properties and behavior of thiophene-based compounds. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic strategies, potentially leading to the discovery of novel compounds with diverse applications.

Upstream product

• 5402-55-1 2-thiophenethanol 
• 7789-60-8 phosphorus tribromide 

Downstream Products

• 30433-91-1 [2-(2-thyenyl)ethyl]amine 
• 106891-32-1 N-methyl-N-(2-(thien-2-yl)ethyl)amine 
• 170482-97-0 (R)-3-[N-2-(2-thienyl)ethyl]amino-5-phenylchroman hydrochloride 
• 141109-20-8 methyl (S)-2-(2-chlorophenyl)-2-[2-(thien-2-yl)ethylamino]acetate 
• 1148154-91-9 (2S)-5-methoxy-N-propyl-N-(2'-(thien-2-yl)ethyl)tetralin-2-amine 
• 1147564-59-7 ((Me)(Ph)(C₄H₃SCH₂CH₂)P)BH₃ 
• 1080649-39-3 2-[2-(3-methyl-4-nitrophenyl)ethyl]thiophene 
• 61440-51-5 4-[2-(2-Thienyl)ethylamino]benzoic Acid 
• 197094-82-9 5-Methyl-2-oxo-5-(2-thiophen-2-yl-ethyl)-cyclohex-3-enecarboxylic acid methyl ester 
• 197094-81-8 4-Methyl-4-(2-thiophen-2-yl-ethyl)-cyclohex-2-enone 
• 923284-19-9 N,N-bis{2-[5-(-trimethylsilylethynyl)-2-thienyl]ethyl}-2-phenylethylamine 
• 923284-30-4 2-[4-(trimethylsilylethynyl)phenyl]-N,N-bis[2-(2-thienyl)ethyl]ethylamine 
• 923284-24-6 N,N-bis[2-(5-ethynyl-2-thienyl)ethyl]-2-phenylethylamine 
• 923284-16-6 N,N-bis[2-(5-iodo-2-thienyl)ethyl]-2-phenylethylamine 

Relevant articles and documents

Directing Drugs to Bugs: Antibiotic-Carbohydrate Conjugates Targeting Biofilm-Associated Lectins of Pseudomonas aeruginosa

Chronic infections by Pseudomonas aeruginosa are characterized by biofilm formation, which effectively enhances resistance toward antibiotics. Biofilm-specific antibiotic delivery could locally increase drug concentration to break antimicrobial resistance and reduce the drug's peripheral side effects. Two extracellular P. aeruginosa lectins, LecA and LecB, are essential structural components for biofilm formation and thus render a possible anchor for biofilm-targeted drug delivery. The standard-of-care drug ciprofloxacin suffers from severe systemic side effects and was therefore chosen for this approach. We synthesized several ciprofloxacin-carbohydrate conjugates and established a structure-activity relationship. Conjugation of ciprofloxacin to lectin probes enabled biofilm accumulation in vitro, reduced the antibiotic's cytotoxicity, but also reduced its antibiotic activity against planktonic cells due to a reduced cell permeability and on target activity. This work defines the starting point for new biofilm/lectin-targeted drugs to modulate antibiotic properties and ultimately break antimicrobial resistance.

Synthesis of remote fluoroalkylated alkenes by a palladium-catalyzed relay Heck-type reaction

Herein, we report a palladium-catalyzed relay Heck-type reaction of fluoroalkyl bromide and terminal alkenes. The reaction involves fluoroalkylation of alkenes and migration of double bonds via a 1,5-hydrogen atom transfer strategy. Through this method, a

Biologically active compounds

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.

A palladium-catalyzed approach to polycyclic sulfur heterocycles

(Chemical Equation Presented) The synthesis of a variety of polycyclic thiophenes and benzothiophenes is accomplished via a palladium-catalyzed domino ortho-alkylation/direct arylation reaction. An examination of the intramolecular direct arylation of thi

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE

A compound which is a pyrrolopyrimidine of formula (I) wherein: R1 is selected from R9 and halogen; R2 is NR6R7; R3 is selected from H, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nAr; R4 is selected from H, C1-C6 alkyl and -(CH2)? Ar; or R3 and R4 form, together with the N and C atoms to which they are attached, a fused five-, six-, seven- or eight-membered N-containing saturated ring which is unsubstituted or substituted; R5 is selected from CN, C02R9,C(O)NR10R11, -(CH2)nOH, -(CH2)nR10Rn, -C=CH, -C(S)NR10R11, -C(NH2)=NOR9, -C(R9)=NOR9, -C(NH2)NH, -C(O)R9 and an unsaturated 5- or 6-membered heterocyclic group which contains 1, 2 or 3 heteroatoms selected from N, O and S and which is unsubstituted or substituted; R6 and R7, which are the same or different, are selected from C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nX and -(CH2)nAr; or R6 and R7 form, together with the nitrogen atom to which they are attached, a saturated five-, six-, seven- or eight-membered heterocyclic group which contains one nitrogen atom and 0 or from 1 to 3 additional heteroatoms selected from N, O and S, which is unsubstituted or substituted and which optionally contains one or two bridgehead atoms; R10and R11,which are the same or different, are selected from H, C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nC3-C10 cycloalkyl and -(CH2)nAr; or R10 and R11 form, together with the nitrogen atom to which they are attached, a saturated five or six membered heterocyclic group which contains a nitrogen atom and 0 or from to 3 additional heteroatoms selected from O, S and N, which is unsubstituted or substituted and which is optionally fused to a benzene ring which is unsubstituted or substituted; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of from 1 to 6; X is selected from -CN, -C02R9 and -NR10R11; R9 is the same or different when more than one is present within a given substituent group and is selected from -H, -QAr, -(CH2) nAr, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nC3-C10cycloalkyl, wherein the cycloalkyl moiety is optionally fused to a benzene ring which is unsubstituted or substituted; Q is C2-C6 alkenylene or alkynylene; and Ar is an unsaturated C6-C10 membered carbocyclic group or an unsaturated 5-11 membered heterocyclic group, which groups are unsubstituted or substituted; or a pharmaceutically acceptable salt thereof. These compounds have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

SULFONAMIDOTHIENYLCARBOXYLIC ACID COMPOUNDS

Compounds represented by the formula STR1 wherein X is halogen, lower alkyl, arylalkyl, alkoxy or hydroxy; wherein the phenyl ring is mono or disubstituted, R' is--COOH or STR2 wherein R" is lower alkyl or aryl and n and m are independently zero, one, two

AMINOACID DERIVATIVES AS ANTIHYPERTENSIVES

The invention relates to new carboxyalkyl dipeptide derivatives and related compounds which are useful as antihypertensives.